Trump, RFK Jr. and Dr. Oz unveil major Medicare plan to cover weight‑loss drugs, tout new drug payment model
President Donald Trump, HHS Secretary Robert F. Kennedy Jr., and CMS Administrator Dr. Mehmet Oz announced a Medicare policy expanding coverage of leading weight‑loss drugs and introducing outcome‑based, risk‑sharing payment deals with manufacturers to lower costs and widen eligibility.
- Medicare coverage expansion: Policy will include leading obesity medications previously excluded from many Part D plans, according to a Fox News press event and Stat News.
- Novel payment models: Deal reportedly uses outcome‑based pricing, risk‑sharing and volume rebates negotiated with manufacturers to reduce Medicare’s costs (Stat News).
- Broader eligibility: Rules expand who can receive these drugs under Medicare, not limited only to the most severe obesity‑related conditions (Fox News press event; Stat News).
What officials announced
President Trump framed the policy as a fulfillment of a pledge to lower drug costs and expand access for older Americans. At a press event aired in full by Fox News, Trump and the administration’s health officials described a major expansion of the Medicare drug benefit to allow qualifying beneficiaries to obtain prescription weight‑loss medications through the program.
HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Mehmet Oz emphasized both public‑health benefits and cost control. They presented the plan as a test of payment models that could be applied to other costly medicines and said expanded access could reduce longer‑term obesity‑related health costs (Fox News).
How the new payment model is described
Reporting by Stat News and comments during the announcement indicate the deal centers on negotiated pricing schemes between Medicare and drugmakers. The arrangements reportedly include:
- Outcome‑based pricing — payments tied to patient results;
- Volume‑based rebates — lower net prices as uptake increases;
- Risk‑sharing — manufacturers agree to price reductions or refunds if specified health targets are not met.
Analysts call the structure a potential blueprint for future Medicare negotiations but note practical challenges in measuring outcomes, tracking adherence, and enforcing refunds (Stat News).
Which drugs and costs are involved
Officials named leading anti‑obesity medications expected to be covered, including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. These medicines have high demand and high list prices; without insurance, monthly costs can exceed $1,000. Drugmakers argue broader coverage will expand access while negotiated terms protect Medicare’s finances (Fox News; Stat News).
Questions analysts are raising
Independent experts caution that while this could be one of the largest Medicare drug‑benefit expansions in recent memory, several implementation details remain unclear. Key concerns include:
- Patient costs: Unclear how much beneficiaries will pay out‑of‑pocket or whether cost‑sharing caps will exist (Stat News).
- Medical necessity rules: CMS has not published full criteria — for example, BMI cutoffs or comorbidity requirements — that will determine eligibility (Fox News; Stat News).
- Budget impact: Higher demand could raise Medicare spending unless safeguards, monitoring and strict enforcement of payment terms are in place (Stat News).
- Oversight and enforcement: Regulators will need clear measurement methods to enforce refunds or price adjustments tied to outcomes (Stat News).
Background: why this matters
Obesity drives chronic disease and health spending across the U.S. Prescription weight‑loss drugs that alter appetite and metabolism have produced meaningful weight reductions in trials and can lower risks tied to diabetes, heart disease and other conditions. Until now, Medicare frequently excluded broad coverage for these medicines, limiting access in many cases. The administration says the new policy marks a shift in handling high‑cost, high‑demand treatments (Fox News; Stat News).
What we do and do not know so far
The primary public record is a 26‑minute press event posted by Fox News and analysis by Stat News. Independent confirmation of long‑term financial or clinical outcomes is not yet available. CMS and HHS are expected to issue implementing rules and guidance clarifying coverage criteria, cost sharing and payment‑model mechanics.
Watch the full event
The administration’s announcement and statements from President Trump, Secretary Kennedy and Administrator Oz are available in full via the Fox News press event.
Implications for San Luis Obispo, California
Economic impact: San Luis Obispo County could experience increased prescription volumes at clinics and pharmacies if Medicare covers weight‑loss drugs widely, producing new revenue streams for medication management and follow‑up care.
Healthcare system strain and opportunities: Smaller practices may need more staff time for counseling, monitoring and documentation required by outcome‑based models, potentially straining resources. Conversely, health systems could qualify for reimbursements tied to outcomes, incentivizing programs that support adherence and maintenance.
Out‑of‑pocket costs for residents: Local beneficiary costs remain unknown. Lower copays might increase uptake and reduce long‑term obesity‑related costs; high copays or strict prior authorization could continue to create barriers.
Political and social effects: Local officials will likely answer constituent questions about access and taxpayer spending. Expanded coverage could shift how obesity is treated and discussed locally, prompting collaboration between community wellness programs and medical providers.
Practical tips: Seniors and disabled residents should monitor CMS guidance on eligibility and coverage rules and consult county Medicare counselors and local clinics for implementation details and prescribing providers.
Reporting notes and sources
This article is based on the administration’s announcement and reporting that includes a full press event and analysis. Primary materials: the full press event posted by Fox News and the Stat News analysis. Follow‑up reporting and official CMS guidance are expected to provide additional, independently verifiable information.
Sources: Fox News (press event); Stat News analysis.
